neeed f lu vvacaccine? · 2014. 4. 10. · j7195 j7195 j7195 j7195 j7194 j7194 j3590 te *all codes...
Post on 08-Feb-2021
0 Views
Preview:
TRANSCRIPT
-
Ne
cine?acVVaclu eed F
ww800To Pro
Ea
ww.MyFluVaccine.com0-843-7477 Order:oduct details pg. 10
arly order discountswill expire soon!
m
A SESIRPRETNEFFFFOMARGORPA
4102LIRPAProduct Catalog
-
Coagulation Products 6
Immune Globulins 8
Hyperimmune Globulins 9
Albumin | Plasma Protein Fraction 9
Inuenza Vaccines and Antivirals 10
Other Vaccines 11
Surgical Sealants 12
Other Specialty Products 12
-
C
F A
Coagulation Products*
TE 5 ML 00944 2948 10 J7192
FACTOR VIII (HUMAN–PLASMA DERIVED)
VON WILLEBRAND FACTOR / FACTOR VIII COMPLEX (HUMAN-PLASMA DERIVED)
FACTOR VIII (RECOMBINANT)
ANTI-INHIBITOR (HUMAN-PLASMA DERIVED)
FACTOR VIIa (RECOMBINANT)
EDOCRERUTCAFUNAMREBMUNCDNEZISNOITPIRCSED
J7192TER XBA
00944-2965-10 VIAL 4000 IU AATE 5 ML ADVVA
TE 5 ML J7192
TER XBA00944-2964-10
VIAL 3000 IU AATE 5 ML ADVVATE 5 ML
J7192TER XBA
00944-2963-10 VIAL 2000 IU AATE 5 ML ADVVA
TE 5 ML J7192
TER XBA00944-2962-10
VIAL 1500 IU AATE 5 ML ADVVATE 5 ML
J7192TER XBA
00944-2961-10 VIAL 1000 IU AATE 5 ML ADVVA
TE 5 ML J7192
TER XBA00944-2960-10
VIAL 500 IU AATE 5 ML ADVVATE 5 ML
J7192TER XBA
00944-2924-02 VIAL 250 IU AATE 5 ML ADVVA
TE 2 ML J7192
TER XBA00944-2923-02
VIAL 1500 IU AATE 2 ML ADVVATE 2 ML
J7192TER XBA
00944-2922-02 VIAL 1000 IU AATE 2 ML ADVVA
TE 2 ML J7192
TER XBA00944-2921-02
VIAL 500 IU AATE 2 ML ADVVATE 2 ML
J7183
TER XBA
67467-0182-02
VIAL 250 IU AATE 2 ML ADVVA
TE J7183
A APHARMTTAPHARMOC67467-0182-01
+VIAL1000 IU WILAATE TE
J7187A APHARMTTAPHARMOC
63833-0617-02 +VIAL500 IU WILAATE
TE P J7187
CSL BEHRING 63833-0616-02
+VIAL2400 IU AATE P HUMTE P
J7187CSL BEHRING
63833-0615-02 +VIAL1200 IU AATE P HUM
TE P J7186
CSL BEHRING 68516-4604-02
+VIAL600 IU AATE P HUMTE
J7186GRIFOLS
68516-4603-02 +VIAL1500 IU ALPHANAATE
TE J7186
GRIFOLS 68516-4602-01
+VIAL1000 IU ALPHANAATE TE
J7186GRIFOLS
68516-4601-01 +VIAL500 IU ALPHANAATE
TE
J7190
GRIFOLS
76125-0667-50
+VIAL250 IU ALPHANAATE
TE DVI J7190
KEDRION 76125-0500-30
VIAL 1000 IU AATE DVI OKTE DVI
J7190KEDRION
76125-0250-20 VIAL 500 IU AATE DVI OK
TE DVI
J7189
KEDRION
00169-7040-01
VIAL 250 IU AATE DVI OK
T J7189
NOVO NORDISK 00169-7050-01
VIAL 8 MG VEN RNOVOSET
J7189NOVO NORDISK
00169-7020-01 VIAL 5 MG VEN RNOVOSE
T J7189
NOVO NORDISK 00169-7010-01
VIAL 2 MG VEN RNOVOSET
J7198
NOVO NORDISK
64193-0225-02
VIAL 1 MG VEN RNOVOSE
EIBA NF J7198
TER XBA64193-0224-02
t II VIAL w/Baxjec2500 IU EIBA NF
J7198TER XBA
64193-0223-02 t II VIAL w/Baxjec1000 IU
EIBA NF TER XBAt II VIAL w/Baxjec500 IU
tsod
ucr
P K
F
F
K
NNNN
F F F
tion
oagu
laC
W
V
WHHHAAAA
K
A
F
AAAAAAAAAA
TE 00944-2845-10 J7192tinuedonc.alueso vCor Reen fing scrderall (800) 843-7477 or check or C+. eryvider and the paoeen the prwi�ed beterodes should be vll c*A
moc.eniccaVulFyM.www|moc.sesirpretneFFF.www|3334-814)008(xaF|7747-348)008(:REDROOT
J7192TER XBA
00944-2844-10 VIAL 2000 IU OMBINAATE REC
TE J7192
TER XBA00944-2843-10
VIAL 1500 IU OMBINAATE RECTE
J7192TER XBA
00944-2842-10 VIAL 1000 IU OMBINAATE REC
TE J7192
TER XBA00944-2841-10
VIAL 500 IU OMBINAATE RECTE
J7192TER XBA
00026-3787-70 VIAL 250 IU OMBINAATE REC
TE FS J7192
ER YBAAY00026-3786-60
VIAL 3000 IU OGENAATE FS KTE FS
J7192ER YBAAY
00026-3785-50 VIAL 2000 IU OGENAATE FS K
TE FS J7192
ER YBAAY00026-3783-30
VIAL 1000 IU OGENAATE FS KTE FS
J7192ER YBAAY
00026-3782-20 VIAL 500 IU OGENAATE FS K
TE FS J7192
ER YBAAY00026-3797-70
VIAL 250 IU OGENAATE FS KTE FS
J7192ER YBAAY
00026-3796-60 T VIAL w/BIOSE3000 IU OGENAATE FS K
TE FS J7192
ER YBAAY00026-3795-50
T VIAL w/BIOSE2000 IU OGENAATE FS KTE FS
J7192ER YBAAY
00026-3793-30 T VIAL w/BIOSE1000 IU OGENAATE FS K
TE FS J7192
ER YBAAY00026-3792-20
T VIAL w/BIOSE500 IU OGENAATE FS KTE FS
J7192ER YBAAY
00053-8135-02 T VIAL w/BIOSE250 IU OGENAATE FS K
TE FS J7192
CSL BEHRING 00053-8134-02
VIAL 3000 IU AATE FS HELIXTE FS
J7192CSL BEHRING
00053-8133-02 VIAL 2000 IU AATE FS HELIX
TE FS J7192
CSL BEHRING 00053-8132-02
VIAL 1000 IU AATE FS HELIXTE FS
J7192CSL BEHRING
00053-8131-02 VIAL 500 IU AATE FS HELIX
TE FS J7192
CSL BEHRING 00944-2948-10
VIAL 250 IU AATE FS HELIXTE 5 ML TER XBAVIAL 4000 IU AATE 5 ML ADVVA
6
-
OFUSE 58394-0016-03
continued
FACTOR VIII (MONOCLONAL PURIFIED)
FACTOR VIII (RECOMBINANT) Continued
FACTOR IX (HUMAN–PLASMA DERIVED)
FACTOR IX (MONOCLONAL PURIFIED)
FACTOR IX (RECOMBINANT)
OTHER COAGULATION PRODUCTS
E
TH EWY58394-0025-03
3000 IU KIT NTHA SOLYXOFUSE TH EWY
58394-0024-03 2000 IU KIT NTHA SOLYX
OFUSE TH EWY58394-0023-03
1000 IU KIT NTHA SOLYXOFUSE TH EWY
58394-0022-03 500 IU KIT NTHA SOLYX
OFUSE TH EWY58394-0015-01
250 IU KIT NTHA SOLYXNTHA TH EWY
58394-0014-01 VIAL 2000 IU YX
NTHA TH EWY58394-0013-01
VIAL 1000 IU YXNTHA TH EWY
58394-0012-01 VIAL 500 IU YX
NTHA TH EWY
00053-7656-05
VIAL 250 IU YX
TE-P CSL BEHRING 00053-7656-04
VIAL 1500 IU MONOCLAATE-P TE-P CSL BEHRING
00944-2933-01 VIAL 1000 IU MONOCLAATE-P
HEMOFIL M TER XBA00944-2932-01
VIAL 1700 IU HEMOFIL M TER XBA
00944-2931-01 VIAL 1000 IU
HEMOFIL M TER XBA00944-2930-01
VIAL 500 IU HEMOFIL M TER XBA
00053-6223-02
VIAL 250 IU
MONONINE CSL BEHRING
58394-0636-03
VIAL 1000 IU
T THEWY58394-0635-03
VIAL 2000 IU BENEFIX RT THEWY
58394-0634-03 VIAL 1000 IU BENEFIX R
T THEWY58394-0633-03
VIAL 500 IU BENEFIX RT THEWY
68516-3200-05
VIAL 250 IU BENEFIX R
OFILNINE SD GRIFOLS 68516-3203-02
VIAL 1700 IU PROFILNINE SD GRIFOLS
68516-3202-02 VIAL 1500 IU PR
OFILNINE SD GRIFOLS 68516-3201-01
VIAL 1000 IU PROFILNINE SD GRIFOLS
64193-0244-02 VIAL 500 IU PR
BEBULIN TER XBA68516-3603-03
VIAL 500 IU ALPHANINE SD GRIFOLS
68516-3602-02 VIAL 1500 IU
ALPHANINE SD GRIFOLS 68516-3601-02
VIAL 1000 IU ALPHANINE SD GRIFOLS
63833-0386-02
VIAL 500 IU
A CSL BEHRING VIAL 500 IU CENTRK
RUTCAFUNAMREBMUNCDNEZISNOITPIRCSED
Coagulation Products
J7185
*EDOCRE
J7185
J7185J7185J7185J7185J7185J7185J7185J7185
J7190J7190
ts
oduc
rtio
n P
oagu
la C
J7190J7190J7190J7190J7190
J7194J7194J7194J7193 J7193J7193
J7193
J7195J7195J7195J7195
J7194 J7194J7194
J3590
TE odes should b ll c*A
AATE NASAL SPRSTIMAP RIASTTAP
A CENTRK
Y . eryvider and the paoeen the prwi�ed beter be v
1.5 ML AAY NASAL SPR1000 M
A 500 IU
00053-6871-00 CSL BEHRING 63833-0891-51
L CSL BEHRING
63833 0386 02 VIAL MG
CSL BEHRING VIAL
J3490J1680J3590
b h h eri�es V
du d o u od Pr odu d Pr o du od u d du d FFF
Pl hl d fd h l h
anufacturer and receipt s product pedigree from the m
uc tyyyct Saf tyeee yetct Saf yytyuc etct Saf non o s ati n ins FF vs InnoF’
f f
vides accurate product lot tracking and recall Pro
by the h
alidate vider to v healthcare pro
n el.e channe our saf
ected within foti�cation to those aff
our hours. ithin f
7
-
IM
I
M 67467-0843-02 J1568
*
MMUNE GLOBULIN (HUMAN) LYOPHILIZED
MUNE GLOBULIN (HUMAN) LIQUID
Immune Globulins
J1568
A APHARMTTAPHARMOC
68209-0843-01
VIAL 2 5 GM GAATTA
M
J1568
AAPHARMTTAPHARMOC
67467-0843-01
VIAL 1 GM GAATTA
M
J1559
AAPHARMTTAPHARMOC
44206-0455-10
VIAL 1 GM GAATTA
A
J1559
CSL BEHRING
44206-0454-04
VIAL 10 GM ZENTR
A
J1559
CSL BEHRING
44206-0452-02
VIAL 4 GM ZENTR
A
J1559
CSL BEHRING
44206-0451-01
VIAL 2 GM ZENTR
A
1
CSL BEHRING
13533-0800-24
VIAL 1 GM ZENTR
C 651J
1
GRIFOLS
13533-0800-71
VIAL 20 GM -MUNEX
C 651J
1
GRIFOLS
13533-0800-20
VIAL 10 GM -MUNEX
C 651J
1
GRIFOLS
13533-0800-15
VIAL 5 GM -MUNEX
C 651J
1
GRIFOLS
13533-0800-12
VIAL 2.5 GM -MUNEX
C 651J
J1557
GRIFOLS
64208-8234-03
VIAL 1 GM -MUNEX
APLEX
J1557
BPL
64208-8234-02
VIAL 10 GM MM
APLEX
J1561
BPL
76125-0900-20
VIAL 5 GM MM
AKED
J1561
KEDRION
76125-0900-10
VIAL 20 GM MM
AKED
J1561
KEDRION
76125-0900-50
VIAL 10 GM MM
AKED
J1561
KEDRION
76125-0900-25
VIAL 5 GM MM
AKED
J1561
KEDRION
76125-0900-01
VIAL 2.5 GM MM
AKED
J1569
KEDRION
00944-2700-07
VIAL 1 GM MM
GARD LIQUID
J1569
TER XBA
00944-2700-06
VIAL 30 GM AMM
GARD LIQUID
J1569
TER XBA
00944-2700-05
VIAL 20 GM AMM
GARD LIQUID
J1569
TER XBA
00944-2700-04
VIAL 10 GM AMM
GARD LIQUID
J1569
TER XBA
00944-2700-03
VIAL 5 GM AMM
GARD LIQUID
J1569
TER XBA
00944-2700-02
VIAL 2.5 GM AMM
GARD LIQUID
J1560
TER XBA
13533-0635-12
VIAL 1 GM AMM
AN S/D
J1460
GRIFOLS
13533-0635-04
VIAL 10 ML ASTTAN S/D M
AN S/D
J1572
GRIFOLS
61953-0005-03
VIAL 2 ML ASTTAN S/D M
A 10% DIF
J1572
GRIFOLS
61953-0005-02
VIAL 20 GM MMBOGA
A 10% DIF
J1572
GRIFOLS
61953-0005-01
VIAL 10 GM MMBOGA
A 10% DIF
J1572
GRIFOLS
61953-0004-05
VIAL 5 GM MMBOGA
A 5% DIF
J1572
GRIFOLS
61953-0004-04
VIAL 20 GM MMBOGA
A 5% DIF
J1572
GRIFOLS
61953-0004-03
VIAL 10 GM MMBOGA
A 5% DIF
J1572
GRIFOLS
61953-0004-02
VIAL 5 GM MMBOGA
A 5% DIF
J1566
GRIFOLS
00944-2658-04
VIAL 2.5 GM MMBOGA
G/ML)
J1566
TER XBA
00944-2656-03
VIAL 10 GM GARD S/D (IGA
-
9
53270-0125-02 ARIZIG
R
Hyperimmune Globulins
ANTI-THYMOCYTE GLOBULIN
BOTULISM IGIV (HUMAN) (BIG-IV)
CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN)
HEPATITIS B IMMUNE GLOBULIN
RABIES IMMUNE GLOBULIN
RHO(D) IMMUNE GLOBULIN
TETANUS IMMUNE GLOBULIN
VARICELLA ZOSTER IMMUNE GLOBULIN
UTCAFUNAMREBMUNCDNEZISNOITPIRCSED
GENT EMER
13533-0634-02
VIAL 125 UNIT VVARIZIG
T S/D GRIFOLS
53270-3000-01
RINGE 250 UNIT SYTEPERYH
WINRHO SDF ANGENE C53270-3100-01
G 15000 IU 3000 MCWINRHO SDF ANGENE C
53270-3500-01 G 5000 IU 1000 MC
WINRHO SDF ANGENE C53270-3300-01
G 2500 IU 500 MCWINRHO SDF ANGENE C
44206-0300-10 G 1500 IU 300 MC
C CSL BEHRING 44206-0300-01
RINGE/10 PK G SY300 MCLAYRHOPHC CSL BEHRING
00562-7805-25 RINGE G SY300 MCLAYRHOPH
M KEDRION 00562-7805-05
RINGE/25 PK G 1 ML SY300 MCRHOGAM KEDRION
00562-7805-01 RINGE/5 PK G 1 ML SY300 MCRHOGA
M KEDRION 00562-7806-35
RINGE G 1 ML SY300 MCRHOGAM KEDRION
00562-7806-05 RINGE/25 PK G 1 ML SY50 MCMICRHOGA
M KEDRION 00562-7806-01
RINGE/5 PK G 1 ML SY50 MCMICRHOGAM KEDRION
13533-0631-02 RINGE G 1 ML SY50 MCMICRHOGA
PERRHO S/D GRIFOLS 13533-0631-06
RINGE G 1 ML SY300 MCYHPERRHO S/D GRIFOLS
13533-0618-10
RINGE G/0.17 ML SY50 MCYH
AB S/D GRIFOLS 13533-0618-02
VIAL 10 ML 150 IU/ML PERRYHAB S/D GRIFOLS
13533-0636-05
VIAL 2 ML 150 IU/ML PERRYH
PERHEP B S/D GRIFOLS 13533-0636-02
VIAL 5 ML YHPERHEP B S/D GRIFOLS
13533-0636-03 RINGE 1 ML SYYH
PERHEP B S/D GRIFOLS 53270-0051-01
RINGE 0.5 ML SYYHM B ANGENE C
53270-0052-01 VIAL 5 ML GAAHEP
M B ANGENE C
44206-0532-11
VIAL 1 ML GAAHEP
M CSL BEHRING
68403-1100-06
VIAL 2.5 GM OGATTOGAYC
BIG MBL
58468-0080-01
VIAL 100 MG YBAB
OBULIN VENSANOFI A AVENTISVIAL 25 MG MOGLYTH
tion
acJ7511
*EDOCRE
NTIS
rei
n F
otrla
sma
Pm
in /
P
903719037190371
J1571 or J1573J1571 or J1573
J0850
J7511 NTIS
lbum
m
une
Glo
bulin
s |
A
J2790J2790 J2788J2788J2788J2790J2788
9037590375
imm
yp
erH
90396
J1670
J2792J2792J2792J2792J2791J2791J2790
ALBUMIN 5% 67467-0623-03 P9045
*
Albumin / Plasma Protein Fraction
tinuedonc. err. yvider and the paoeen the prwi�ed beterodes should be vll c*A
P9045P9045P9045P9047P9047P9045P9045P9047P9047P9045P9045P9047P9047P9045P9045P9047P9047P9045
AAPHARMTTAPHARMOCAAPHARMTTAPHARMOCAAPHARMTTAPHARMOCAAPHARMTTAPHARMOC
GRIFOLSGRIFOLSGRIFOLSGRIFOLSCSL BEHRING CSL BEHRING CSL BEHRING CSL BEHRING CSL BEHRING CSL BEHRING CSL BEHRING CSL BEHRING KEDRIONKEDRIONKEDRION
68209-0623-0368209-0623-0267467-0623-0268516-5216-02 68516-5216-01 68516-5214-02 68516-5214-01 44206-0251-10 44206-0251-05 44206-0310-50 44206-0310-25 00053-7680-33 00053-7680-32 00053-7670-3200053-7670-3176125-0784-1076125-0784-2576125-0785-25
500 ML 500 ML250 ML250 ML 100 ML 50 ML 500 ML 250 ML 100 ML50 ML500 ML250 ML 100 ML50 ML 500 ML250 ML100 ML50 ML250 ML
ALBUMIN 5%ALBUMIN 5%ALBUMIN 5%ALBUTEIN 25% ALBUTEIN 25%ALBUTEIN 5% ALBUTEIN 5%
X 25% ALBURX 25% ALBURX 5% ALBURX 5% ALBUR
ALBUMINAR 25% ALBUMINAR 25% ALBUMINAR 5%ALBUMINAR 5%ALBUKED 25% ALBUKED 25% ALBUKED 5%
EDOCRERUTCAFUNAMREBMUNCDNEZISNOITPIRCSED
9
-
als
vir AL
A
9065649281-0014-50 ONE
*
TE 5% 13533-0613-25 P9043
*
continued
n�uenza Vaccines & Antivirals
15
P9043P9047P9047P9046P9045 P9041P9047P9047P9047P9047P9045P9045P9047P9047P9047P9047
GRIFOLSGRIFOLSGRIFOLSGRIFOLSGRIFOLSGRIFOLSGRIFOLSKEDRION
TERXBATERXBATERXBATERXBATERXBA
AAPHARMTTAPHARMOCAAPHARMTTAPHARMOCAAPHARMTTAPHARMOCAAPHARMTTAPHARMOC
00026-0613-20 13533-0692-71 13533-0692-20 13533-0692-16 13533-0685-25 00026-0685-20 76179-0025-0100944-0493-0200944-0493-0100944-0490-0200944-0491-0200944-0491-0168209-0643-0267467-0643-02 68209-0643-0167467-0643-01
250 ML PPF50 ML PPF100 ML 50 ML20 ML 250 ML 50 ML50 ML 100 ML50 ML50 ML500 ML250 ML100 ML 100 ML 50 ML50 ML
ANAATE 5% LASMTE 5% ANAATE 5% LASM
LASBUMIN 25% LASBUMIN 25% LASBUMIN 25% LASBUMIN 5% LASBUMIN 5% EDBUMIN 25%EXBUMIN 25%EXBUMIN 25%
TE 25%UMINAATE 25%TE 5%UMINAATE 5%TE 5%UMINAATE 5%
LBUMIN 25%LBUMIN 25%LBUMIN 25%LBUMIN 25%
Albumin / Plasma Protein Fraction EDOCRERUTCAFUNAMREBMUNCDNEZISNOITPIRCSED
Q2038ASTEUR SANOFI P
49281-0394-15 0.5 ML PFS UZ
ONE 90658
ASTEUR SANOFI P66521-0117-02
VIAL 5 ML 10 DS UZUVIRIN
90658/Q2037TIS ARNOVVAR
66521-0117-10 0.5 ML PFS
UVIRIN 90672
TIS ARNOVVAR66019-0301-10
VIAL 5 ML 10 DS ALENT
90686MEDIMMUNE
19515-0894-52 ER YAAYANASAL SPR0.2 ML INTRADRIVVALENT UMIST QU
ALENT 90688
OSMITHKLINE XGLA19515-0891-11
0.5 ML PFS ADRIVVALENT AL QUVVAL QUULAAVALENT
90658/Q2036OSMITHKLINE XGLA
19515-0893-07 VIAL 5 ML 10 DS ADRIVVALENT AL QUVVAL QUULAAV
AL 90661
OSMITHKLINE XGLA63851-0113-01
5 ML MDV VVAL ULAAVX
90673TIS ARNOVVAR
TBD 0.5 ML PFS AVVAUCELLV
OK 90686
TEIN SCIENCES OPR58160-0901-52
0.5 ML SDV UBLALENT
90656OSMITHKLINE XGLA
33332-0114-01 0.5 ML PFS ADRIVVALENT ARIX QUU
URIA 90658/Q2035
BIOCSL 33332-0114-10
0.5 ML PFS FLURIA BIOCSL VIAL 5 ML 10 DS FL
-FLUENZA VACCINES 2014EDOCRERUTCAFUNAMREBMUNCDNEZISNOITPIRCSED
tivnci
nes
& A
acVue
nza
PL PL PL KE FL FL BUBUBUAL AL AL
n�
tion
| I
acrei
n F
otra
P
AF
PL
I
INF
PLPL PL PL
AF
lasm
a lb
umin
/ P
A
UFLUFLU FLU FLU FLUFLUFLUFLUFLUFLUFL
AF
AL SUSP
ANTIVIRALS
vider and th oeen the prwi�ed beterodes should be vll c*A
6 MG/M U ORMIFLATTAU 75 MG MIFLATTA
ALENT 0.5 ML ADRIVVALENT ONE QUUZFLALENT 0.5 ML ADRIVVALENT ONE QUUZFLALENT 0.25 ML ADRIVVALENT ONE QUUZFLALENT 5 ML 10 ADRIVVALENT ONE QUUZFL
AL 0.1 ML ADERMONE INTRUZFLONE HIGH-DOSE 0.5 ML UZFL
000 . err. y he pa
000 ML
492
AP 10 PK C
492 SDV
492 PFS
492 L PFS
492 VIAL 0 DS
492 PFS PFS
004-0820-09 GENENTECH 004-0800-85 GENENTECH
281-0414-10 SANOFI P281-0414-50 SANOFI P281-0514-25 SANOFI P281-0621-15 SANOFI P281-0709-55 SANOFI P281-0395-65 SANOFI P
J8499J8499
TECH
90686
TECH
90686 ASTEUR I P
90685ASTEUR I P
90688ASTEUR I P
90654ASTEUR I P
90662ASTEUR I PASTEUR I P
EHTKCIPUOY
yF.Mwww|(800) 843-7477
PUOYYTITNAUQ
om.ccineacluVF
EWETADEHTKCI
REVILED
10
-
TUBERSOL 49281-0752-21
R
Other Vaccines
ASTEU SANOFI P49281-0820-10
TEST VIAL 10 1 ML OID ADS UPS ASTEU SANOFI P
49281-0215-15 0.5 ML SDV/10 PK XOTANUS TTANUS TE
C ASTEU SANOFI P49281-0215-10
10 PFS/BX ATENIVVAC ASTEU SANOFI P
00006-4133-41 10 SDV/BX ATENIVVA
TD ABSORBED CK MER00006-4047-20
10 PK SDV VIRUS, LIVE CK MER
00006-4047-41 TUBES/25 PK 2 ML AAVIRUS, LIVE TTAOTEQ RAATEQ RTTAOR
VIRUS, LIVE CK MER00006-4981-00
TUBES/10 PK 2 ML AAVIRUS, LIVE TTAOTEQ RAATEQ RTTAORX HB PED/ADOLESC CK MER
00006-4094-09 G/0.5 ML 10 PK 5 MCAOMBIVVAREC
T CK MER00006-4995-41
G PFS/6 PK 10 MCX HB ADUL LT AOMBIVVARECT CK MER
00006-4992-00 VIAL/10 PK G 10 MCX HB ADUL LT AOMBIVVAREC
SIS CK MER00006-4093-09
G SDV 40 MCYX HB DIAL LYAOMBIVVARECX HB PED/ADOLESC CK MER
00006-4995-00 G/6 PK PFS 5 MCAOMBIVVAREC
T CK MER63851-0501-01
G/SDV 10 MCX HB ADUL LT AOMBIVVARECABIES TIS ARNOVVAR
00005-1971-02 UENT W/DILSDV T RVERABAAVERR
VNAR 13 PFIZER 00006-4739-00
PFS/10 PK PREX 23 CK MER
00006-4943-00 VIAL 2.5 ML APNEUMOVVA
X 23 CK MER49281-0510-05
0.5 ML SDV/10 PK APNEUMOVVACEL ASTEU SANOFI P
00006-4897-00 SDV/5 PK APENTTA
X HIB CK MER00006-4681-00
0.5 ML SDV/10 PK APEDVVAMMR II MEASLES MUMPS CK MER
00006-4673-00 0.5 ML SDV/10 PK
X CK MER49281-0489-01
0.5 ML SDV/10 PK AMERUVVAMENOMUNE ASTEU SANOFI P
49281-0589-05 SDV
A ASTEU SANOFI P42515-0001-01
SDV/5 PK TRCMENAO TIS ARNOVVAR
49281-0860-10 0.5 ML PFS IXIAR
VIRUS ASTEU SANOFI P49281-0250-51
5 ML MDV IPOL POLIO ABIES ASTEU SANOFI P
00006-4045-00 UENT W/DIL1 SDV X IM RAIMOVVA
ASIL HPV CK MER00006-4045-41
VIAL 0.5 ML GARDASIL HPV CK MER
49281-0225-10 10 0.5 ML SDV GARD
OID ASTEU SANOFI P49281-0286-10
10 SDV PF PEDS XOTANUS TTANUS TEDIPHTHERIA AND CEL ASTEU SANOFI P
49281-0400-10 10 SDV/BX AAPTTAD
AP) ASTEU SANOFI P49281-0400-15
10 SDV/BX TDCEL (AADAP) ASTEU SANOFI P
49281-0545-05 5 PFS/BX TDCEL (AAD
THIB ASTEU SANOFI PUENT W/DILG 10 MCCAUTCAFUNAMREBMUNCDNEZISNOITPIRCSED
90715
*
90648UR UR
EDOCRE
cine
sc90733
90734UR
90738UR
9071390675
UR
90649UR
906499071490700
UR
90715UR
90715UR UR
acVth
er
O
90740 or 90747
90744 90746906759067090732907329069890647
UR
9070790706
8658090703
R
90714 R
90714R
90714R
906809068090744
90743 or 90746
90743 or 90746
90740 or 90747
X 00006-4963-00 90736
90736CK MER
00006-4963-41 SDV AVVAAAVOSTTAZ
X 90716
CK MER00006-4827-00
SDV/10 PK AVVAAAVOSTTAZX
90716CK MER
00006-4826-00 0.5 ML SDV/10 PK AARIVVAVVARIV
X 90633
CK MER00006-4831-41
0.5 ML SDV AARIVVAVVARIVA
90633CK MER
00006-4095-09 25 U/0.5 ML SDV/10 PK TTA QAVVA
A 90632
CK MER00006-4096-09
25 U/1 ML PFS/6 PK TTA QAVVAA
90691CK MER
49281-0790-51 50 U/1 ML PFS/6 PK TTA QAVVA
PHOID 90691
ASTEUR SANOFI P49281-0790-20
0.5 ML/PFS YTVI PHIM YTPHOID
86580ASTEUR SANOFI P
49281-0752-22 10 ML MDV YTVI PHIM YT
TUBERSOL ASTEUR SANOFI PTEST VIAL 50 5 ML
moc.eniccaVulFyM.www|moc.sesirpretneFFF.www|3334-814)008(xaF|7747-348)008(:REDROOT
. err. yvider and the paoeen the prwi�ed beterodes should be vll c*A
11
-
Surg
ical
Sea
lant
s |
Oth
er S
peci
alty
Pro
duct
s
Surgical Sealants
Disposable Containers DESCRIPTION MANUFACTURER
Other Specialty Biopharmaceuticals DESCRIPTION SIZE NDC NUMBER MANUFACTURER CODE*
Syringes DESCRIPTION
Complimentary Support Material DESCRIPTION TO ORDER OR SUBSCRIBE OR FOR MORE INFORMATION
DESCRIPTION SIZE NDC NUMBER MANUFACTURER CODE*
SHARPS COMPLIANCE SHARPS COMPLIANCE SHARPS COMPLIANCE SHARPS COMPLIANCE SHARPS COMPLIANCE SHARPS COMPLIANCE SHARPS COMPLIANCE
1-QUART SHARPS RECOVERY SYSTEM1.5-QUART SHARPS RECOVERY SYSTEM1-GALLON SHARPS RECOVERY SYSTEM2-GALLON SHARPS RECOVERY SYSTEM3-GALLON SHARPS RECOVERY SYSTEM5-GALLON SHARPS RECOVERY SYSTEM for use with non-sharps biohazard waste only20-GALLON SHARPS RECOVERY SYSTEM
BERINERT 500 IU VIAL 63833-0825-02 CSL BEHRING J0597 THROMBATE III 500 IU VIAL 13533-0603-20 GRIFOLS J7197
Specialty Pharmaceuticals DESCRIPTION SIZE NDC NUMBER MANUFACTURER CODE*
ATRYN 1750 IU VIAL 42976-0121-02 rEVO Biologics J7196 CLOLAR 20 MG/ML VIAL 58468-0100-01 SANOFI AVENTIS J9027 CUBICIN 500 MG SDV/10 PK 67919-0011-01 CUBIST J0878 HEMABATE 1 ML VIAL/10 PK 00009-0856-08 PFIZER J3490 MOZOBIL 20 MG/1.2 ML VIAL 58468-0140-01 SANOFI AVENTIS J2562 ZALTRAP 5 ML VIAL 00024-5840-01 SANOFI AVENTIS J9400 ZALTRAP 10 ML VIAL 00024-5841-01 SANOFI AVENTIS J9400
AVAILABLE UPON REQUEST
BIOSUPPLY TRENDS QUARTERLY MAGAZINEIG LIVING! MAGAZINEBIOSUPPLY TRENDS eNEWSLETTERPRODUCT REFERENCE CHARTSSEASONAL FLU POSTERFLU MYTHS AND FACTS BROCHUREeCOMMUNICATION ALERTSEDUCATIONAL TELECONFERENCESIVIG REIMBURSEMENT CALCULATORPRODUCT CATALOG
All complimentary support materials are available to order on the FFF website.
TO ORDER: (800) 843-7477 | Fax (800) 418-4333 | www.FFFenterprises.com | www.MyFluVaccine.com
*All codes should be veri#ed between the provider and the payer.
TISSEEL 2 ML VHSD VALUPAK 00944-4201-04 BAXTER J3590, C9399 TISSEEL 4 ML VHSD VALUPAK 00944-4201-08 BAXTER J3590, C9399 TISSEEL 10 ML VHSD VALUPAK 00944-4201-12 BAXTER J3590, C9399 TISSEEL VHSD KIT 2 ML 00944-4201-03 BAXTER J3590, C9399 TISSEEL VHSD KIT 4 ML 00944-4201-07 BAXTER J3590, C9399 TISSEEL VHSD KIT 10 ML 00944-4201-11 BAXTER J3590, C9399
12
-
SaSaSaSaleleleles s s s SuSuSuSupppppppporororort t t t anananand d d d WoWoW w!w! C Cusustotomemer CaaCaare™
FrF om our in-house teams of cususstomem r cacacareree
rereprpresesenentatatit veves,s,, a a advdvd isisorors s anand d adadvovocacacatetes,s,s t t to o ououour r r
nanatitiononalal ! !eleld d teteamam o of f tetet rrrititi ororory y mamananan gegersrsrs, , , ,
ththerere e isis always a responsive, dedicated d exexpepertrt
to take care of f yourur n neeeedsds..
OuOur r WoWow!w!!! C C C Cusussu tototot memem r r CaCarere
professionals are here t to o susuppp ort you.
E mergency ordering and shipping 24/7/7/363655
On-caallll p pharmacist
Veri!ed Electtroronic Pedigree™ for every order
Lot-Track™ tracking and recall noti!cation
BioSupply™ online ordering and reporting
Specialty publicatioons for current industry
and inventory newss
Expert advisors
Patient advocates
Nationwide, robust sales force of professionals
SupportInfusion Advisor Line
Our infusion specialists will answer
your questions about the principles
of intravenous and subcutaneous
infusion therapy, cost-effective care
and improving patient outcomes.
Pharmacy Advisor Line
Our on-call pharmacists have the
expertise to answer your product
or dosing questions about every
drug provided by FFF.
Reimbursement Advisor Line
Our reimbursement specialists are
ready to resolve your questions and
guide you through the complexities
of biopharmaceutical reimbursement.
P
O
R
O
Advisor Lines
FFF ENTERPRISES
-
ResourcesBBBEEYYYYYOOOOONNNNNDDDDD DDDIISS N,,ISTRIBUTTIONN FFFFF ENTERPRISESS iiss pleaaaassseed ttooo pprroovviiddeee mmmeeeaannniiinnnggggffffuuuullll ccccoooommmmmmmmuuuunnnniiiiccccaaaa----
ttttiooonnss ffoor ppppaaa aalltthhccaarree pprroovviddeerss,, bbbrriinnggggiiiinngggggg ffffooooccccuuuussss aaanndd innsigghht into the complexities off tthhee aaaaaaatttiieennttss aanndd hheeaall
ssppppeeeeciaaallltttyyy ccaalllss mmaarrrrkkkeetttpppplllaaaaccccee,, aass wweellll aass vvaaaallluuuaaabbbblleeee rrrreeesssoouuuurrrcceess ttoo hheelpp oourr cuustommerrs pprroovviiddee yyyyyyy pppppharmaceutica
ttthheeee bbbeesstt ir patients – it’s one more way wwee’rree sstt ccaarree ffoorr tthheiir HHeeeellllppiiinnngggg HHHeeeeaaaalllltttthhhhccccaaaarrrreeee CCCCaaaarreee®®!!!
This complimentary magazine published by FFF is the denitive source for news, trends and information for the biopharmaceutical marketplace. BSTQ earned top honors with several 2013 MarCom Awards.
> Subscribe and view our online edition at: www.BSTQuarterly.com
IG Living! is the only magazine that delivers comprehensive healthcare and immune globulin information, community and reimbursement news, and resources for successful living directly to immune globulin patients and their healthcare providers.
> Subscribe and view our online edition at: www.IGLiving.com
FFF’s award-winning enewsletter, BioSupply Trends, is a bi-monthly publication to update customers, analysts and others who seek insight into the complexities of the specialty pharmaceuticals marketplace.
> Subscribe online at: www.FFFenterprises.com.
BioSupply Trends eNewsletter
IG Living! Magazine
BioSupply Trends Quarterly Magazine
14
-
Flu Myths and Facts Brochure
eCommunication Alerts
Product Reference Charts
• Seasonal In!uenza Vaccine • Immune Globulin• Hyperimmune Globulin• Anti-Inhibitor Factor VIIa & IX• Factor VIII
FFF’s complimentary Product Reference Charts are highly valued educational resources for comparative product information.
> Customers can order the following charts on the FFF website:
Seasonal Flu Poster
FFF provides complimentary seasonal !u posters in English and Spanish to our customers to help them plan and promote their !u vaccination clinics.> Posters may be ordered on the FFF website.
Our complimentary patient-focused brochures demystify the seasonal !u virus and highlight the bene"ts of receiving the vaccine. Because the !u is preventable, and the vaccine changes each year, it’s important to dispel the myths about the disease and provide information about how people can best protect themselves and their loved ones.
> Myths and Facts Brochures may be ordered on the FFF website.
Updates on seasonal and pandemic in!uenza conditions, marketplace news and information, plus ecommunications tailored to meet the needs of individual customer groups, as well as alerts that advocate for patients and patient organizations.
Additional Resources
Experts focus on trending topics and answer questions that are prevalent in the biopharmaceuticals marketplace.
Educational Monthly Teleconferences IVIG Reimbursement Calculator
Find the current reimbursement rate for IVIG, based on the CMS published ASP rates for Physician O$ce and Hospital Outpatient facilities.
> Available at: www.FFFenterprises.com
15
-
WHAT YOU SHOULD KNOW ABOUT HEMOLYTIC DISEASE OF THE NEWBORN (HDN)
What is hemolytic disease of the newborn (HDN)?
sensitization or alloimmunization
COOMBS TEST
QUESTIONS AND ANSWERS
Please see adjacent page for brief summary of full prescribing information.
Reactions to RhO(D) immune globulin (human) are infrequent in RhO(D)-negative individuals and consist primarily of slight soreness at the site of injection and slight temperature elevation. While sensitization to repeated injections of human immunoglobulin is extremely rare, it has occurred.
r
p
p
c
t
p
Printed in USA. December 2013 HY36-1213
-
HyperRHO® S/D Full DoseRho(D) Immune Globulin (Human)Solvent /Detergent Treated
BRIEF SUMMARYCONSULT PACKAGE INSERT FOR FULL PRESCRIBING
INFORMATIONFOR INTRAMUSCULAR INJECTION ONLY
INDICATIONS AND USAGEPregnancy and Other Obstetric ConditionsRho(D) Immune Globulin (Human) — HyperRHO® S/D Full Doseis recommended for the prevention of Rh hemolytic disease of thenewborn by its administration to the Rho(D) negative mother within72 hours after birth of an Rho(D) positive infant, providing thefollowing criteria are met:1. The mother must be Rho(D) negative and must not already be
sensitized to the Rho(D) factor.2. Her child must be Rho(D) positive, and should have a negative
direct antiglobulin test (see PRECAUTIONS).If HyperRHO S/D Full Dose is administered antepartum, it isessential that the mother receive another dose of HyperRHO S/DFull Dose after delivery of an Rho(D) positive infant.If the father can be determined to be Rho(D) negative,HyperRHO S/D Full Dose need not be given.HyperRHO S/D Full Dose should be administered within 72 hoursto all nonimmunized Rho(D) negative women who have undergonespontaneous or induced abortion, follow ing ruptured tubalpregnancy, amniocentesis or abdominal trauma unless the bloodgroup of the fetus or the father is known to be Rho(D) negative. Ifthe fetal blood group cannot be determined, one must assumethat it is Rho(D) positive, and HyperRHO S/D Full Dose should beadministered to the mother.TransfusionHyperRHO S/D Full Dose may be used to prevent isoimmuni -zation in Rho(D) negative individuals who have been transfusedwith Rho(D) positive red blood cells or blood componentscontaining red blood cells.
CONTRAINDICATIONSNone known.
WARNINGSHyperRHO S/D Full Dose is made from human plasma.Products made from human plasma may contain infectiousagents, such as viruses, and, theoretically, the Creutzfeldt-Jakob Disease (CJD) agent that can cause disease. The riskthat such products will transmit an infectious agent has beenreduced by screening plasma donors for prior exposure tocertain viruses, by testing for the presence of certain currentvirus infections, and by inactivating and/or removing certainviruses. Despite these measures, such products can stillpotentially transmit disease. There is also the possibility thatunknown infectious agents may be present in such products.Individuals who receive infusions of blood or plasma productsmay develop signs and/or symptoms of some viral infections,particularly hepatitis C. ALL infections thought by a physicianpossibly to have been transmitted by this product should bereported by the physician or other healthcare provider toGrifols Therapeutics Inc. [1-800-520-2807]. The physician should discuss the risks and benefits of thisproduct with the patient, before prescribing or administering itto the patient.NEVER ADMINISTER HYPERRHO S/D FULL DOSEINTRAVENOUSLY. INJECT ONLY INTRAMUSCULARLY. NEVERADMINISTER TO THE NEONATE.
Rho(D) Immune Globulin (Human) should be given with caution topatients with a history of prior systemic allergic reactions followingthe administration of human immunoglobulin preparations.The attending physician who wishes to administer Rho(D)Immune Globulin (Human) to persons with isolated immuno -globulin A (IgA) deficiency must weigh the benefits of immuni -zation against the potential risks of hypersensitivity reactions.Such persons have increased potential for developing antibodiesto IgA and could have anaphylactic reactions to subsequentadministration of blood products that contain IgA.As with all preparations administered by the intramuscular route,bleeding complications may be encountered in patients withthrombocytopenia or other bleeding disorders.
PRECAUTIONSGeneralA large fetomaternal hemorrhage late in pregnancy or followingdelivery may cause a weak mixed field positive Du test result. Ifthere is any doubt about the mother’s Rh type, she should begiven Rho(D) Immune Globulin (Human). A screening test todetect fetal red blood cells may be helpful in such cases.If more than 15 mL of D-positive fetal red blood cells are presentin the mother’s circulation, more than a single dose ofHyperRHO S/D Full Dose is required. Failure to recognize thismay result in the administration of an inadequate dose.Although systemic reactions to human immunoglobulinpreparations are rare, epinephrine should be available fortreatment of acute anaphylactic reactions.Drug InteractionsOther antibodies in the Rho(D) Immune Globulin (Human)preparation may interfere with the response to live vaccines suchas measles, mumps, polio or rubella. Therefore, immunizationwith live vaccines should not be given within 3 months afterRho(D) Immune Globulin (Human) administration.Drug/Laboratory InteractionsBabies born of women given Rho(D) Immune Globulin (Human)ante partum may have a weakly positive direct antiglobulin test atbirth.Passively acquired anti-Rho(D) may be detected in maternalserum if antibody screening tests are performed subsequent toantepartum or postpartum administration of Rho(D) ImmuneGlobulin (Human).Pregnancy Category CAnimal reproduction studies have not been conducted withHyperRHO S/D Full Dose. It is also not known whetherHyperRHO S/D Full Dose can cause fetal harm whenadministered to a pregnant woman or can affect reproductioncapacity. HyperRHO S/D Full Dose should be given to a pregnantwoman only if clearly needed.Pediatric UseSafety and effectiveness in the pediatric population have not beenestablished.
ADVERSE REACTIONSReactions to Rho(D) Immune Globulin (Human) are infrequent inRho(D) negative individuals and consist primarily of slightsoreness at the site of inject ion and slight temperature elevation.While sensitization to repeated injections of human immuneglobulin is extremely rare, it has occurred. Elevated bilirubin levelshave been reported in some individuals receiving multiple dosesof Rho(D) Immune Globulin (Human) following mismatchedtransfusions. This is believed to be due to a relatively rapid rate offoreign red cell destruction.
Grifols Therapeutics Inc.Research Triangle Park, NC 27709 USAU.S. License No. 1871 08941119-BS
© 2013 Grifols Inc. All rights reserved. Printed in USA. December 2013 HY36-1213
-
First FVIII/VWF product in the US stable for 3 years, up to the expiration date printed, when stored at or below 77°F (25°C). Do not freeze.
Please see brief summary of Alphanate® Full Prescribing Information below.
For more information: Grifols Inc.Customer Service: 888 325 8579 Fax: 323 441 7968
Grifols Biologicals Inc.5555 Valley Boulevard, Los Angeles, 90032 CA - USA Tel. 888-GRIFOLS (888 474 3657)
www.grifolsusa.com
The Power of FVIII/VWF Complex
Convenient Room Temperature Storage
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use Alphanate Antihemo-philic Factor/von Willebrand Factor Complex (Human) safely and effectively. See Full Prescribing Information for Alphanate.
ALPHANATE (ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX [HUMAN]) Sterile, lyophilized powder for injection
For Intravenous Use Only
Initial U.S. Approval: 1978
INDICATIONS AND USAGEAlphanate is an Antihemophilic Factor/von Willebrand Factor Complex (Human) indicated for:
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
To report SUSPECTED ADVERSE REACTIONS, contact Grifols Biologicals Inc. at 1-888-GRIFOLS (1-888-474-3657) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS
First FVIII/VWF product in the US stable for 3 years, up to the expiration date printed, First FVIII/VWF product in the US stable for 3 years, up to the expiration date printed,
© 2012 Grifols Biologicals Inc. All rights reserved. Printed in USA. January 2012 A803-0911
-
See full prescribing information for Privigen.
W
R
E
Risk factors for hemolysis include high
d
Serious a
Use only if clearly needed.
B
2 3 11:30 AM
t
l
tsseeggrrgLaLaezi SaliaVill biAA availab
0 pt
e!!
telel 0
a
0 n 4g
4I
4V
4 I
4n
4I
0 e4v4i4r4P44e
4h
40 r
0 eh
e4 t
4g0 g4i4
0 py
gd0 g: An a0 0 g0 n 40 g
gd ge gd g
0 e0 r0 u0 u4a4e4m4y-0 -0 o4d4a4e4R4Simple choicg4gu4ss o0 rgest vial size of IVIg available
t ce4
ovides the lar
e
Pr
Simple storage helf sp Occupies less sh
0 Simple administration
0 g ge gi gn0 n0 o0 c0 % I0 se 10 u gi giqu0 vial size of IVIg available
ge
g pace than two 20-g cartons for mor
tion
e v0 of0 f c0 e Ig V0 0 l0 g
gficient storage
g ef
gce gn ge gd g
Simple administration Reduces the number of vials to open and handle for infusions of 40 g or mor
tion of vials to open and handle for infusions of 40 g or mor
e ons of 40 g or mor
Important S Privigen is ind immunodefici
aise platel to r
TARNING:WWARNING:
Safety Informationapy for patients with primary immunodeficiency (PI) associated with defects in humor dicated as replacement ther
cong ed agammaglobulinemia, X-linkiency (CVID), let counts in patients with chronic immune thrombocytopenic purpur
AAND SFUNCTION Y RENAL D,THROMBOSIS
rimary immunodeficiency (PI) associated with defects in humorott-Aldrich syndromeWisk enital agammaglobulinemia,
a (ITP). bocytopenic purpur
AILURECUTE RENAL F FAILUREA
including but not limited to common v,al immunity ects in humor P . and severe combined immunodeficiencies, rome
ariable to common v Privigen is also indicated
Privigen is conwith antibodi
In patients at Ensure that p
hrombosis m T,infrequently
eit ,Hemolysisand high doseincreased risk
aindicated in patients with history of anaphylac ntr who have had hypersensitivity reactions es to IgA,
monitor uri , risk for developing acute renal failure atients with preexisting renal insufficiency or othe
even in the absence of might occur with Privigen, aseptic meningitis syndrome (AMS) may occur—
ascular or due to enhanced red blood ce av ther intr Closely monitor patients for hemolysis and hem . es
acute kidney injury or vo hemolysis k of thrombosis
ctic or severe systemic reaction to human immune gatients with IgA deficiency and antibodies to IgA P.
including blood urea nitrogen and serum creatinine; ne output and renal function, rwise predisposed are not volume-depleted and ad
atients could also experience hyperproteinemia, P. known risk factors) and/or —more frequently with high doses (2 g/kg
can develop subsequent to treatment.ation, ell sequestr Consider the relative risks and benefits before prescribing high-dose regimen for chronic ITP in patients at molytic anemia.
Monitor patients for pulmonary adverse reactions and signs of tr olume overload
and in IgA-deficient patients in patients with hyperprolinemia, globulin, A are at greater risk of severe hypersensitivity and anaphylactic reactions
discontinue if renal function deterior a nitrogen and serum creatinine;ate of infusion en at the minimum r dminister Privig
or hyponatremia;, increased serum viscosity ce hyperproteinemia,apid infusion. r
underlying inflammation,, Risk factors include non-O blood group ment. efits before prescribing high-dose regimen for chronic ITP in patients at
ansfusion-related acute lung injury (TRALI). dverse reactions and signs of tr
IgA-deficient patients. anaphylactic reactions
.ates al function deterior.acticable pr
r hyponatremia;
erlying inflammation, onic ITP in patients at
acute lung injury (TRALI).
increased risk
Privigen is de completely el
In clinical stu ele pain,pain,
and dizziness
In clinical stu ,TT,positive DA
adverse react
reatment wit TTreatment with Privigen might interfere with a patient’In patients ove
Privigen is manuegPrivigen is a r
acute kidney injury or vo , hemolysis, k of thrombosis
ansmissio he risk of trT erived from human plasma. iminated.
dies of patients being treated with Privigen for P diarrh abdominal pain,,atureated body temper ev
, Serious adverse reactions were hypersensitivity. s
dies of patients being treated with Privigen for ch increases in vomiting,, epistaxis nausea, anemia,
as aseptic meningitis syndrome (AMS). tion w
s response th Privigen might interfere with a patient’ er 65 or in any patient at risk of developing renal in
ed by CSL Behring AG and distributed by CSL Beh ufactured trademark of CSL Behring AG.gister
Monitor patients for pulmonary adverse reactions and signs of tr olume overload.
the including viruses and,,on of infectious agents
the most common adverse reactions observed I, joint chest pain, stomach discomfort, cough, hea,
and increased body temper, dizziness, fatigue, chills
the most common adverse reactions seen in >5% of subjects were headache, hronic ITP P, decreas conjugated and unconjugated bilirubin,
accines and could lead to misinterpretation of serologic testing. to live virus v do not exceed recommended dose and infuse Privigen at the minimum r, sufficiency
hring LLC.
ansfusion-related acute lung injury (TRALI). dverse reactions and signs of tr
ob disease (CJD) agent,ak the Creutzfeldt-J, eoretically
naus, fatigue, in >5% of subjects were headache pharyngolaryngeal pain,,e illness influenza-lik swelling/effusion,
.ature mper
ated body temper elev, een in >5% of subjects were headache and increased blood lactate dehydrogenase ed hematocrit,
Use in pregnant women only if clearly needed. tation of serologic testing..acticableate pr infuse Privigen at the minimum r
acute lung injury (TRALI).
cannot be gent,
back vomiting,, chills sea, urticaria, olaryngeal pain,
,atured body temperA serious . drogenase
only if clearly needed.
©2013 CSL Be ven 1020 First A
.CSLBehrwwww.CSLBehring-us.com
hring LLC A 19406-0901 USAnue, PO Box 61501, King of Prussia, P PA 19406-0901 USA
ring-us.com .Privigen.comwwww.Privigen.com PVG13-11-0038
12/2013
-
Privigen®Immune Globulin Intravenous (Human), 10% LiquidInitial U.S. Approval: 2007
BRIEF SUMMARY OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use Privigen safely and effectively. See full prescribing information for Privigen.
WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURESee full prescribing information for complete boxed warning.
Thrombosis may occur with immune globulin products, including Privigen. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IGIV) products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Privigen does not contain sucrose.
For patients at risk of thrombosis, renal dysfunction or renal failure, administer Privigen at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
------------------------------------INDICATIONS AND USAGE----------------------------------Privigen is an Immune Globulin Intravenous (Human), 10% Liquid indicated for the treatment of:
Primary humoral immunodeficiency (PI) Chronic immune thrombocytopenic purpura (ITP)-------------------------------DOSAGE AND ADMINISTRATION-----------------------------Intravenous Use Only
Indication Dose Initial InfusionRate
Maintenance Infusion Rate (as tolerated)
PI 200-800 mg/kg (2-8 mL/kg) every 3-4 weeks
0.5 mg/kg/min (0.005 mL/kg/min)
Increase to 8 mg/kg/min (0.08 mL/kg/min)
ITP 1 g/kg (10 mL/kg) for 2 consecutive days
0.5 mg/kg/min (0.005 mL/kg/min)
Increase to 4 mg/kg/min (0.04 mL/kg/min)
Ensure that patients with pre-existing renal insufficiency are not volume depleted, and discontinue Privigen if renal function deteriorates.
For patients at risk of renal dysfunction or thrombosis, administer Privigen at the minimum dose and infusion rate practicable.--------------------------------DOSAGE FORMS AND STRENGTHS-------------------------Privigen is a liquid solution containing 10% IgG (0.1 g/mL).
---------------------------------------CONTRAINDICATIONS ----------------------------------- History of anaphylactic or severe systemic reaction to human immune globulin
Hyperprolinemia (Privigen contains the stabilizer L-proline) IgA-deficient patients with antibodies to IgA and a history of hypersensitivity
------------------------------WARNINGS AND PRECAUTIONS------------------------------- IgA-deficient patients with antibodies to IgA are at greater risk of developing severe
hypersensitivity and anaphylactic reactions. Monitor renal function, including blood urea nitrogen and serum creatinine, and urine
output in patients at risk of developing acute renal failure. Thrombosis may occur with immune globulin products, including Privigen. Hyperproteinemia, increased serum viscosity, and hyponatremia may occur. Aseptic meningitis syndrome (AMS) may occur, especially with high doses or rapid
infusion. Hemolysis that is either intravascular or due to enhanced red blood cell sequestration
can develop subsequent to Privigen treatments. Risk factors for hemolysis include high doses and non-O blood group. Closely monitor patients for hemolysis and hemolytic anemia.
Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]).
Carefully consider the relative risks and benefits before prescribing the high dose regimen (for chronic ITP) in patients at increased risk of thrombosis, hemolysis, acute kidney injury, or volume overload.
Privigen is made from human blood and may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
------------------------------------ADVERSE REACTIONS------------------------------------- PI – The most common adverse reactions, observed in >5% of study subjects, were
headache, fatigue, nausea, chills, vomiting, back pain, pain, elevated body temperature, abdominal pain, diarrhea, cough, stomach discomfort, chest pain, joint swelling/effusion, influenza-like illness, pharyngolaryngeal pain, urticaria, and dizziness. Serious adverse reactions were hypersensitivity, chills, fatigue, dizziness, and increased body temperature.
Chronic ITP – The most common adverse reactions, observed in >5% of study subjects, were headache, elevated body temperature, positive direct antiglobulin test (DAT), anemia, nausea, epistaxis, vomiting, blood bilirubin unconjugated increased, blood bilirubin conjugated increased, blood total bilirubin increased, hematocrit decreased, and blood lactate dehydrogenase increased. A serious adverse reaction was aseptic meningitis.
To report SUSPECTED ADVERSE REACTIONS, contact CSL Behring Pharmacovigilance at 1-866-915-6958 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
----------------------------------DRUG INTERACTIONS---------------------------------------The passive transfer of antibodies may:
Lead to misinterpretation of the results of serological testing. Interfere with the response to live virus vaccines.
----------------------------USE IN SPECIFIC POPULATIONS--------------------------------- Pregnancy: No human or animal data. Use only if clearly needed. Geriatric: In patients over age 65 or in any patient at risk of developing renal
insufficiency, do not exceed the recommended dose, and infuse Privigen at the minimum rate practicable.
Based on November 2013 revision.
-
Where delivering vaccines is our mission
bioCSL, previously CSL Biotherapies, understands the
bioCSL is a trademark of CSL Limited.©2014 bioCSL Inc., 1020 First Avenue, PO Box 60446, King of Prussia, PA 19406-0446www.biocsl-us.com BCSL14-03-0004 4/2014
bioCSL has invested in one of the only high-speed
-
W R
ak ak
ith W
TTa
ke
e
ke Cont Cont
o echnolo RFID T
of Your o
olol
om FFFogy fr
Invento t tr tr
ory y
W
distributes evious st pr
passive RF erified Inv Ve
R ith R
Plus..
W
s – leaving you ee to focus i
fre torage location n and conditi
a FID technology y to track, tra g ogr Consig
o –ram ventory Pr
echnolo e o echnolo e
..
RFID T RFID Te
e. s on patient carod e pro on of the critical-car
ace, and verify the moment of use, statuses ™gnment (VIPc)
om FFFom FFFogy frogy fr
ducts FFF t of use,
e-of-the-art,
Eli ihighEliminahi h va
Increase
high-va
tlue critical productsoducts
ctes carrying cosl i i l
ts ofd
es visibility of pro oduct
lue critical pr
Monit,
ors remotely priquantityquantity l, loca loca i dtion andtion and
temperature
r d
oduct d
iseprer©2014 FFF Ent
(800) 84 VIPManager@FFFenterprises.com.nc, Is
43-7477 x1142 | VIPManager@FFFenterprises.com
ager@FFFenterprises.com
-
s to us as tomer
s a DISTRIBUTORs see us as MUCH
R.H M
MORE.
r
v oomers prcust
, FFF g escesourr
eams of o our tt
ABAFFORDFROM
.tstienor their pae fo vide the best car
o help tDISTRIBUTIONONDBEY goes olio of industtfo essionals and porofe pr
,YABILITAILVAAVANDYTSAFE, YBILIT
p our
y tr
h e mwhich w
eing HlpeH
pxE
b h e all our actions. uras me
is the b arethcare Cale
IDFFFehtecneirep
l h onsider e c We
y enchmark b
!ECNEREFFI
this no
.ya wonly, but the yat the FFF wt jus o ww
cerprises.ent.FFFww.ncerprises, Int14 FFF E20©
77477443-) 8800om | (c
-
(800) 843-7477 www.FFFenterprises.comFL215 0414
More than words, it is our commitment to a secure pharmaceutical supply chain.
top related